Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

robot
Abstract generation in progress

Sensei Biotherapeutics announced an inducement grant to a new employee of an option to purchase 166,435 shares of common stock, effective March 11, 2026. This grant adheres to Nasdaq Listing Rule 5635©(4) and involves an exercise price of $29.37, vesting over four years. Sensei Biotherapeutics is a clinical-stage biotechnology company focused on cancer therapeutics, with its lead program PIKTOR targeting endometrial and breast cancer.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin